Emergency department (ED) visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder (SSD), results of a large population-based study […]

Canada’s National Guideline for the Clinical Management of Opioid Use Disorder (OUD) has been updated to reflect the latest literature. The new document recommends buprenorphine and […]

New research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD). In a 52-week phase 2 trial, personalized rTMS applied over […]

The combination of intranasal insulin (INI) and the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin had positive effects on cognition and immune and inflammatory biomarkers in patients […]

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia […]

In a world that is more connected than ever, a silent epidemic is taking its toll. Overall, 1 in 3 US adults report chronic loneliness — […]

A finger-prick blood test can accurately identify p-tau217 — a key biomarker of Alzheimer’s disease (AD) — without the need for temperature or storage control measures. […]

Combining cognitive remediation (CR) with transcranial direct current stimulation (tDCS) was associated with slower cognitive decline for up to 6 years in older adults with major […]